Table 1.
Controls | DBS-DA | DBS+DA | t statistic χ2 or F- statistic |
p-value | |
---|---|---|---|---|---|
Participants (no.) | 17 | 13 | 14 | ||
Gender (male) | 14 | 12 | 11 | χ2 =1.0 | 0.6 |
Age (years) | 59.9±10.4 | 60.0±7.2 | 55.9±10.0 | F=0.8 | 0.4 |
Age PD of diagnosis | 46.1±7.5 | 40.1±8.1 | t=1.8 | 0.08 | |
PD Disease duration (years) | 13.3±4.8 | 15.0±4.9 | t=0.9 | 0.37 | |
DBS (years) | 3.6±2.4 | 3.9±2.3 | t=0.3 | 0.7 | |
LEU dose(mg/day) L-dopa (mg/day) |
613.3±379.0 558.6±308.4 |
794.3±292.2 600.0±327.5 |
t=1.8 t=0.3 |
0.085 0.7 |
|
UPDRS on | 16.5±1.2 | 15.2±1.2 | t=1.1 | 0.2 |
UPDRS = Unified Parkinson’s Disease Rating Scale; LEU = L-dopa equivalent units;
All values are mean ± SD.
Parkinson’s disease patients who underwent deep brain stimulation and were treated with (DBS+DA) and without a dopamine agonist (DBS-DA).